SeaStar Medical to Present at the Virtual Emerging Growth Conference on June 12, 2024
SeaStar Medical, a commercial-stage medical device company listed on Nasdaq as ICU, will present at the Virtual Emerging Growth Conference on June 12, 2024. CEO Eric Schlorff will conduct a fireside chat at 12:35 p.m. Eastern time to provide an overview of the company and its Selective Cytopheretic Device (SCD). The chat will also discuss recent company updates. Investors can submit questions in advance or attend the live event. An archived webcast will be available 48 hours post-event on SeaStar Medical's website.
- Potential increase in market visibility and investor interest due to CEO's presentation at a significant industry conference.
- Opportunity for investors to gain insights and updates directly from the CEO, enhancing transparency and trust.
- Availability of an archived webcast provides continued access to important company information beyond the live event.
- No disclosure of specific new developments or financial results in the press release could limit immediate investor impact.
- The announcement might be perceived as a routine update, lacking substantial new information to significantly drive stock performance.
DENVER, June 06, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that Eric Schlorff, CEO, will hold a fireside chat at the Virtual Emerging Growth Conference on Wednesday, June 12 at 12:35 p.m. Eastern time (9:35 a.m. Pacific time).
During the fireside chat, Mr. Schlorff will provide an overview of SeaStar Medical and the Selective Cytopheretic Device (SCD), and discuss Company updates. Investors can submit questions in advance of the event at Questions@EmergingGrowth.com.
Investors can register to attend the live event here. An archive webcast of the fireside chat will be available approximately 48 hours following the event on the SeaStar Medical website.
About SeaStar Medical
SeaStar Medical is a commercial-stage medical technology company that is redefining how extracorporeal therapies may reduce the consequences of excessive inflammation on vital organs. SeaStar Medical’s novel technologies rely on science and innovation to provide life-saving solutions to critically ill patients. The Company is developing and commercializing cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. For more information visit www.seastarmedical.com or visit us on LinkedIn or X.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1955. These forward-looking statements include, without limitation, SeaStar Medical’s expectations with respect to the ability of SCD to treat patients with AKI and other diseases; the expected regulatory approval process and timeline for commercialization; and the ability of SeaStar Medical to meet the expected timeline. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to access funding under existing agreements; (vi) the risk that third-parties suppliers and manufacturers are not able to fully and timely meet their obligations, (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services, (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property, and (ix) other risks and uncertainties indicated from time to time in SeaStar Medical’s Annual Report on Form 10-K, including those under the “Risk Factors” section therein and in SeaStar Medical’s other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
SeaStar Medical Contact:
LHA Investor Relations
Jody Cain
(310) 691-7100
Jcain@lhai.com
# # #
![](https://ml.globenewswire.com/media/MTU3MzY0YjAtOTY0OC00OGY4LTk2YzYtYWUwZGMzZTg1Mzk1LTUwMDExMDY3Ng==/tiny/SeaStar-Medical-Holding-Corpor.png)
FAQ
When is SeaStar Medical presenting at the Virtual Emerging Growth Conference?
Who will represent SeaStar Medical at the Virtual Emerging Growth Conference?
What will be discussed during SeaStar Medical's fireside chat?
Where can investors submit their questions for SeaStar Medical's presentation?